Compare Johnson Controls International PLC (JCI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Viatris Inc — how do they compare? Johnson Controls International PLC trades at $141.07 (market cap $85.03B), while Viatris Inc trades at $17 (market cap $19.79B). The key difference: Johnson Controls International PLC is far larger — about 4.3× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| JCI | VTRS | |
|---|---|---|
Market Cap | $85.03B | $19.79B |
Sector | Industrials | Health |
52-Week High | $148.21 | $17.39 |
52-Week Low | $103.24 | $8.74 |
Enterprise Value | $93.86B | $32.00B |
Dividend Yield | 1.15% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls (JCI) trades at $139.03, down 1.02% today, with technical indicators showing bearish momentum despite strong analyst support. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $1.19 versus $1.12, maintaining a pattern of earnings outperformance. Recent corporate developments include a $0.40 dividend declaration and board appointments, while cash flow trends show improvement with projected positive net cash flow of $157M for 2026.
JCI presents a compelling investment case with 62% analyst buy ratings and a $158.29 consensus price target offering 14% upside. However, elevated valuation multiples (P/E 42.95, EV/EBITDA 26.89) and bearish technical signals warrant caution. Key risks include competitive pressures in building technologies and sensitivity to commercial construction cycles, balanced by strong profitability margins and institutional confidence.
Viatris (VTRS) trades at $17.10, down 1.1% today but maintains a bullish technical outlook with strong moving average signals. The company shows mixed fundamentals with recent earnings beats but negative profitability metrics, while analyst consensus leans toward Hold with a $20 price target. Recent positive developments include FDA acceptance of new drug applications and pipeline progress in biosimilars.
Viatris presents a value opportunity with reasonable P/S and P/B ratios, but faces challenges with negative margins and high debt. The stock's upside potential depends on successful pipeline execution and debt reduction, while risks include competitive pressures and execution missteps in a challenging pharmaceutical market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
